Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Screening for Immunodeficiencies in Children With Invasive Pneumococcal Disease: Six-year Experience From a UK Children's Hospital

Bijker EM. et al, (2022), Pediatric Infectious Disease Journal, 41, 575 - 578

Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials

Billard MN. et al, (2022), Journal of Clinical Epidemiology, 147, 11 - 20

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.

Marchevsky NG. et al, (2022), EBioMedicine, 81

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus.

Sheerin D. et al, (2022), Cell Biosci, 12

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

Li G. et al, (2022), Lancet, 399, 2212 - 2225

Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.

Rollier CS. et al, (2022), Vaccine

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Shaw RH. et al, (2022), Lancet Respir Med

Viral vector vaccines.

McCann N. et al, (2022), Curr Opin Immunol, 77

Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial

MAIDEN M. et al, (2022), Vaccine

Future reporting of vaccine uptake needs to include any change in ethnic or socioeconomic disparities.

Hoang U. et al, (2022), BMJ, 377

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.

Munro APS. et al, (2022), Lancet Infect Dis

Towards better reporting of the Proportion of Days Covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS.

Dalli LL. et al, (2022), Br J Clin Pharmacol

Osteoarticular Infections in Pediatric Hospitals in Europe: A Prospective Cohort Study From the EUCLIDS Consortium

Trobisch A. et al, (2022), Frontiers in Pediatrics, 10

Healthcare workers’ mental health and wellbeing during the COVID-19 pandemic: Longitudinal analysis of interview and social media data

Vera San Juan N. et al, (2022)

Prevention of typhoid by Vi conjugate vaccine and achievable improvements in household WASH: Evidence from a cluster-randomized trial in Dhaka, Bangladesh.

Tadesse BT. et al, (2022), Clin Infect Dis

Non-Tuberculous Mycobacterial Infection of the Retropharyngeal Space.

Weng A. et al, (2022), Pediatr Infect Dis J

Next-generation T cell–activating vaccination increases influenza virus mutation prevalence

Bull MB. et al, (2022), Science Advances, 8

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.

Liu X. et al, (2022), J Infect

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.

Mok CKP. et al, (2022), Respirology, 27, 301 - 310

Two-year follow-up of infant and maternal outcomes after planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial.

Beardmore-Gray A. et al, (2022), BJOG

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?